（编辑 任世碧） 证券日报网讯 11月18日晚间，金城医药发布公告称，公司之全资子公司山东金城生物药业有限公司于 近日收到欧洲药品质量管理局（EDQM）核准签发的谷胱甘肽原料药欧洲药典适用性证书（简称"CEP 证书"）。 ...

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]

格隆汇11月18日丨金城医药（维权）(300233.SZ)公布，全资子公司山东金城生物药业有限公司（简 称"金城生物"）于近日收到欧洲药品质量管理局（EDQM）核准签发的谷胱甘肽原料药欧洲药典适用性 证书(简称"CEP证书"），本次金城生物获得谷胱甘肽原料药CEP证书，表明该原料药已符合欧洲药典标 准，可在欧洲市场进行销售。本次获得CEP证书有助于金城生物进一步扩展海外市场，提升公司在原料 药市场的竞争力。 ...

本次金城生物获得谷胱甘肽原料药CEP证书，表明该原料药已符合欧洲药典标准，可在欧洲市场进行销 售。本次获得CEP证书有助于金城生物进一步扩展海外市场，提升公司在原料药市场的竞争力。 金城医药(300233.SZ)发布公告，公司之全资子公司山东金城生物药业有限公司(以下简称"金城生物")于 近日收到欧洲药品质量管理局(EDQM)核准签发的谷胱甘肽原料药欧洲药典适用性证书(以下简称"CEP 证书")。 ...

山东金城医药集团股份有限公司 关于子公司收到原料药 CEP 证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之全资子公司山东金城生物药业有限公司（以下 简称"金城生物"）于近日收到欧洲药品质量管理局（EDQM）核准签发的谷胱甘肽原 料药欧洲药典适用性证书(以下简称"CEP 证书"），现将相关情况公告如下： 一、药品基本情况 原料药名称：谷胱甘肽 生产企业：山东金城生物药业有限公司 证书生效日期：2025 年 11 月 17 日 证券代码：300233 证券简称：金城医药 公告编号：2025-079 证书编号：CEP 2024-255-Rev 00 二、药品相关信息 谷胱甘肽是一种含γ-酰胺键和巯基的三肽，由谷氨酸、半胱氨酸及甘氨酸组成， 是一种细胞内重要的代谢调节物质，在维持细胞生物功能方面起重要作用。谷胱甘肽 中半胱氨酸上的巯基为其活性基团，易与某些药物、毒素等结合，使其具有整合解毒 作用。另外，谷胱甘肽还具有抗自由基、抗衰老、抗氧化、提高人体免疫力、保护肝 脏、抑制脂肪肝的形成，防止皮肤老化及色素沉着、改善皮肤抗氧化 ...

Core Viewpoint - Jincheng Pharmaceutical experienced a decline of 1.40% on November 17, with a trading volume of 153 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On November 17, Jincheng Pharmaceutical had a financing buy-in amount of 26.78 million yuan and a financing repayment of 17.89 million yuan, resulting in a net financing buy of 8.88 million yuan. The total financing and margin balance reached 460 million yuan, accounting for 6.80% of the circulating market value, which is above the 70th percentile of the past year [1]. - The company’s financing balance of 460 million yuan is considered high, reflecting significant investor interest [1]. Short Selling Summary - On the same day, Jincheng Pharmaceutical repaid 500 shares in short selling and sold 12,000 shares, amounting to 211,200 yuan at the closing price. The short selling balance stood at 56,320 yuan, which is above the 50th percentile of the past year, indicating a relatively high level of short selling activity [1]. Company Overview - Jincheng Pharmaceutical, established on January 12, 2004, and listed on June 22, 2011, is located in Zibo City, Shandong Province. The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [1]. - The revenue composition of Jincheng Pharmaceutical includes 34.59% from formulation products, 26.61% from other pharmaceutical and chemical products, 21.88% from cephalosporin side-chain active esters, and 16.92% from biopharmaceuticals and specialty active ingredients [1]. Shareholder Information - As of November 10, the number of shareholders for Jincheng Pharmaceutical reached 26,700, an increase of 0.46% from the previous period. The average circulating shares per person decreased by 0.46% to 13,903 shares [2]. - The company has distributed a total of 933 million yuan in dividends since its A-share listing, with 323 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is the Fuguo Precision Medical Flexible Allocation Mixed Fund, holding 4.96 million shares as a new shareholder. The Hong Kong Central Clearing Limited is the eighth largest shareholder, holding 3.34 million shares, a decrease of 2.14 million shares from the previous period. The ninth largest shareholder is the Xingquan Light Asset Mixed Fund, holding 3 million shares as a new shareholder [3].

证券日报网讯 金城医药（300233）11月17日在互动平台回答投资者提问时表示，截至2025年11月10日 公司股东总户数为26735户。 ...

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received a medical device registration certificate for its product, a medical gynecological gel, from the Beijing Drug Administration [1] Group 1: Product Overview - The medical gynecological gel consists of a gel and a vaginal applicator, designed to form a protective gel membrane on the vaginal wall [1] - The product aims to provide physical isolation from external bacteria, preventing the colonization of pathogenic microorganisms [1] - It assists in the prevention of gynecological infectious diseases, such as vaginitis, by creating a protective barrier against microbial invasion [1] Group 2: Market Implications - The gel offers daily protection for women's vaginal health and serves as an auxiliary safeguard during postoperative recovery periods [1]

每经AI快讯，金城医药（SZ 300233，收盘价：17.85元）11月14日晚间发布公告称，山东金城医药集团 股份有限公司之全资子公司北京金城泰尔制药有限公司于近日收到北京市药品监督管理局下发的《中华 人民共和国医疗器械注册证》。产品名称为"医用妇科凝胶"。 每经头条（nbdtoutiao）——展望"十五五"|专访财科院院长杨志勇：遏制地方政府新增隐性债务，债务 信息要透明，尽可能降低利息成本 （记者 王瀚黎） 2024年1至12月份，金城医药的营业收入构成为：医药制造业占比100.0%。 截至发稿，金城医药市值为69亿元。 ...

人民财讯11月14日电，金城医药（300233）11月14日公告，公司全资子公司北京金城泰尔制药有限公司 近日收到北京市药监局下发的医用妇科凝胶医疗器械注册证。 ...